Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
60.6 BRL | +28.17% | +4.83% | +0.18% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.83 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.18% | 7.91TCr | - | ||
-3.15% | 713.1Cr | B- | ||
+21.25% | 357.99Cr | B- | ||
-9.18% | 292.8Cr | B- | ||
+16.05% | 169.31Cr | - | ||
-8.50% | 118.79Cr | - | ||
-33.05% | 110.83Cr | B | ||
-36.85% | 105.25Cr | C- | ||
-27.92% | 94Cr | - | ||
-16.90% | 87Cr | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Z1TS34 Stock
- Ratings Zoetis Inc.